These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: CHA2DS2-VAS(C) and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation.
    Author: Glotzer TV, Hellkamp AS, Lee KL, Lamas GA.
    Journal: Can J Cardiol; 2015 Aug; 31(8):1004-11. PubMed ID: 26076964.
    Abstract:
    BACKGROUND: CHA2DS2-VASc and CHADS2 scores were derived and validated for stroke-risk stratification in patients who have a diagnosis of atrial fibrillation (AF). We hypothesized that these scores would predict adverse cardiovascular events even in the absence of AF. METHODS: The CHA2DS2-VASc and CHADS2 scores for 2010 patients with sick sinus syndrome who underwent pacemaker implantation and were enrolled in the Mode Selection Trial (MOST) were calculated. The association of these risk scores with main trial end points, including the composite of death and stroke, were evaluated to determine whether the associations differed by history of AF. RESULTS: Of the 2010 patients, 12% had a CHA2DS2-VASc score of 0-1, 16% had a score of 2, 41% had a score of 3-4, and 31% had a score ≥ 5 (the distribution for CHADS2 was similar); 42% had a clinical history of AF. Both scores were associated with death or stroke (hazard ratio [HR], 1.14; 95% confidence interval [CI], 1.05-1.23 for each 1-point increase in CHA2DS2-VASc; P = 0.001; HR, 1.11; 95% CI, 1.02-1.21 for each 1-point increase in CHADS2; P = 0.016). Association of scores with outcomes of death, stroke, and heart failure hospitalization were not different for patients with vs those without a history of AF (interaction P ≥ 0.55 for CHA2DS2-VASc and ≥ 0.30 for CHADS2). CONCLUSIONS: Both CHA2DS2-VASc and CHADS2 scores predict risk of death or stroke in patients with sick sinus syndrome, regardless of AF history. These scores could be risk-stratification tools for clinical events that might respond to new therapies—ie, anticoagulation or other interventions—even in the absence of AF.
    [Abstract] [Full Text] [Related] [New Search]